Featured
What the Grey Market Costs: Price Per Milligram
Live inventory across 30+ China vendors, reduced to the going rate per milligram for the top peptides - and cross-checked against whether the dose is actually in the vial.
Read the report GuideLab Testing 101 for the Grey-Market Peptide Scene
How third-party COA testing actually works — the labs, the tests and what each proves, the costs, and how to read (and spot a fake) certificate of analysis.
Read the reportThe feed
Original analysis and explainers from our own COA corpus — not third-party abstracts. Filter by cluster or topic.
-
The $150,000 rugpull: Eric Ranks, 'Mr. Based,' and the Peptide University fake-vendor machine
The Peptide University group-buy "rugpull," explained: how "Mr. Based," Eric Ranks, and the vendors "Bella" and RX Anabolics took roughly $150,000 from members — with the crypto traced on-chain to Coinbase, Binance and OKX. The same grey-market playbook, run at least twice: stand up a vendor nobody can verify, vouch it into trust, funnel members' money, then blame the vendor.
-
FDA scientists recommended against all seven peptides. The panel voting July 23 was rebuilt to say yes anyway.
On June 30, 2026, three weeks before the FDA Pharmacy Compounding Advisory Committee votes on seven peptides, the agency's own staff scientists recommended against all seven on insufficient-evidence grounds. The panel that votes July 23-24 was reconstituted with members who prescribe, produce, and promote peptides. A follow-up to our April preview, corrected against the record: the real agenda is 7 peptides (not 14), nothing is being "restored," the last peptide vote went 0-for-7, and our 22,762 lab reports answer a question the FDA is not asking.
-
Retatrutide Costs $0.78/mg at the Source. Resellers Charge You 3x to 22x for the Same Vial.
We priced six of the most-bought research peptides at the source, the per-mg number one hop below the US reseller layer, against the cheapest reseller (DisclosedLabs) and the vendor median (PeptideBase). Retatrutide runs $0.78/mg at the source and $10.00/mg at the reseller median, a 12.9x markup. Tirzepatide is 22.3x. We walk through the relabel supply chain that makes the same vial cost 3x to 22x more under a domestic brand, ask the two fair questions about price aggregators, and stay honest about the real grey-market risks, which is why we publish the COAs.
-
GLP-1s and Hair Loss: One Real Signal, One Shaky One, and the Users Who Never Show Up in the Data
A pharmacovigilance study of seven GLP-1 drugs found hair loss reported 23 percent more often and reproductive disorders 6.6 times more often in the WHO safety database, with semaglutide the loudest. We read the actual paper: why the hair-loss signal is a class-wide weight-loss effect, not an Ozempic quirk, why the reproductive number is loud but probably confounded, and why the millions self-sourcing GLP-1s grey-market are invisible to the whole system.
-
Over-filled, or short-changed? What 15,167 COAs say about grey-market peptide dosing
Are grey-market peptides correctly dosed? We collected 22,588 certificates of analysis from independent labs and measured the 15,167 that report a dose against the label. The counterintuitive finding on grey-market peptide dose accuracy: most vials are over-filled, not short. Over-fills are common and shallow; under-fills are rarer but run deeper. The full per-compound breakdown, and why the independent-lab-only cut tells the honest story.
-
The Mystery Retatrutide Patient: One Person Got Early Access While Millions Wait
A single unnamed patient was granted early access to the unapproved weight-loss drug retatrutide through the FDA compassionate-use pathway. A coincidence of age set off speculation about who it was; the White House denied it. The plain-language version of what was reported, what is actually confirmed, and why the real story for grey-market buyers is the access gap.
-
Peptides for Aging Bones and Joints: What's Proven, What's Hype
Can peptides heal aging bones and joints? Every candidate mapped by evidence tier: bone-building is proven FDA medicine, while the joint, tendon, and cartilage claims are strong in animals but unproven in humans.
-
Pharma's Quality Bar Is Lower Than You Think. We Measured 22,559 Grey-Market Peptide Tests Against It.
"Pharmaceutical grade" is the grey market's favorite phrase. We read the rules pharma actually follows, the real USP and FDA limits, and they are looser than most buyers assume: a compliant drug can be 10% off its label, and 95% purity can pass for a peptide. Then we measured 22,559 grey-market peptide certificates against those exact bars. The dose gap is real but survivable. The purity number is a decoy. The endotoxin gap is the one that should change how you buy.
-
Does DSIP Actually Work? An Honest Evidence Review
Does DSIP actually work? The honest evidence read: tiny old studies (n=6-16), the best-controlled trial weak-to-negative, no receptor or gene in 49 years, and no modern RCTs. Research-use-only.
-
XTP Peptides Underfilled Its Retatrutide, Then Refused to Honor Its Own Guarantee
Between late May and June 2026, customer-commissioned independent lab tests on products from XTP (known in channels as Xi'an Taiye Chemical Co.) found a multi-product quality collapse: a Janoshik group test on its R30 retatrutide returned roughly 4mg of a labeled 30mg product in two of three vials, GHK-Cu underfilled by ~21mg, and Tesamorelin-10 below the vendor's own published refund threshold, which the vendor then refused to honor. This is a dated, source-linked account of what the certificates show, what buyers reported, and why none of it was in any aggregator until now.
-
CJC-1295 is the dirtiest peptide we test: 19% of vials fail purity (vs 0.2% for tirzepatide)
Across 269 third-party CJC-1295 assays in the TitrateLab corpus, nearly one in five tests below 90% purity — roughly 76× the failure rate of tirzepatide and 49× retatrutide. This is a dated, certificate-linked breakdown of which batches failed, by how much, and when, with every vendor claim sitting beside its own certificate of analysis. No editorializing beyond what the certificates show.
-
The Peptide Vendor Graveyard: every verified shutdown, exit scam, and FDA action 2018-2026
A dated, cited archive of every major enforcement action, vendor shutdown, lab controversy, and regulatory milestone in the research peptide grey market from 2018 through April 2026. Primary sources only. Updated as events happen. This is the canonical reference for "what happened to that vendor" — so you stop relying on Reddit rumors and forum memory.
-
The July 23 PCAC review could collapse the peptide grey market's core demand. Here's what's at stake.
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee meets to review whether BPC-157, TB-500, and ~12 other peptides should be restored to Category 1, a move HHS Secretary RFK Jr. announced on JRE #2461 back in February. If approved, compounding pharmacies could legally dispense these compounds for the first time since September 2023, and the grey-market moat that built Peptide Sciences, Amino Asylum, and the rest collapses. What the community needs to know before the vote.
-
HGH is discussed 88× more than it's tested. Here's what the 70 batches we have show.
Across a 19-month window, HGH appeared in 6,172 peptide-tagged Discord messages in our corpus. Our Certificate-of-Analysis database contains 70 HGH assays, substantially more than earlier versions of this article after a MESO-Rx analytical-lab subforum crawl and Janoshik public-portal backfill. The 88× gap between how much people discuss it and how much anyone verifies it is still the largest testing gap of any compound we track. Here's what the 70 batches show, and why HGH remains the hardest compound on this market to actually verify.
-
The peptide grey market collapsed in 9 months. Quality got dramatically better at the same time.
Between June 2025 and March 2026 the research-peptide grey market lost its three biggest players: Amino Asylum to an FDA raid, Science.bio to voluntary closure, and Peptide Sciences to a regulatory reversal. We measured what happened to quality across 8,452 tested batches from 294 manufacturers, and the story nobody is telling is that purity went up.
Free tools
Have a Certificate of Analysis we don't?
Drop it here. Anonymous by design — no account, no email, your IP is hashed weekly for abuse-prevention only. We OCR it, parse it, and add it to the corpus that powers every vendor page on this site. The long tail (Telegram-only sellers, niche OEMs) only gets covered if customers with skin in the game contribute one.
Latest indexed studies
Browse all 7978 →- Anti-ENO1 antibody HuL001 blocks TGFβ activation and metabolic rewiring in pancreatic cancer
- Gold nanoparticle nanovaccines with LLO or GAPDH peptides prevent neonatal listeriosis better than ampicillin in pregnant mice.
- Review Consolidates Evidence for Targeted Therapies in ALK, ROS1, RET, NTRK, NRG1 Fusion-Driven Lung Cancers
- OVASIS (GnRHa) at 1.0 mL/kg BW optimizes captive breeding in ornamental snakehead Channa andrao.
- Water-soluble β-strand peptidomimetics designed for diverse sequences and aqueous target binding
- Setmelanotide emerges as key pharmacologic intervention for hypothalamic obesity, targeting `MC4R` pathway amidst complex management challenges.
- Aquatic Exercise Program to Assess Cognition and Mobility in Older Adults with Cognitive Decline
- Longitudinal study protocol to investigate HIIT-induced neurophysiological and psychomotor plasticity in Parkinson's disease
- Prospective Cohort to Investigate Protein Intake, Nutritional Status, and Recovery After Hip Fracture
- Long-term Somatropin (Norditropin®) treatment in adults evaluated for safety and efficacy
- TTA-121 Trial Commences to Address Autism Spectrum Disorder
- Tranexamic Acid Efficacy in Preventing Postpartum Hemorrhage After Elective C-Section to be Assessed in Large RCT
Browse by peptide
- Semaglutide 1011
- Tirzepatide 722
- Insulin 534
- Liraglutide 479
- Oxytocin 354
- Mgf 196
- LL-37 165
- Retatrutide 153
- THYMOSIN-ALPHA-1 147
- Mots-c 121
- BPC-157 115
- IGF-1 109
- GHRP-6 107
- SS-31 98
- MK-677 96
- Ghk-cu 94
- GHRP-2 92
- Sermorelin 89
- Orexin a 87
- Epitalon 83
- Melanotan-ii 80
- Cagrilintide 74
- Selank 74
- Semax 74
- PT-141 72
- P21 64
- Hgh 45
- Humanin 45
- Ipamorelin 45
- Dulaglutide 42